Alethia Young
Stock Analyst at Cantor Fitzgerald
(4.82)
# 91
Out of 4,423 analysts
100
Total ratings
61.54%
Success rate
49.74%
Average return
Main Sectors:
36 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $968.00 | -12.19% | 7 | Oct 16, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | $46 | $16.15 | +184.83% | 4 | Sep 12, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $16.95 | +6.19% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $16.51 | +263.42% | 3 | Sep 7, 2023 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Overweight | $16 | $21.99 | -27.24% | 5 | Aug 22, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.40 | +275.00% | 2 | Aug 22, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $79 → $47 | $24.72 | +90.13% | 3 | Aug 8, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $11.92 | +185.23% | 2 | Jul 6, 2023 | |
| NEXI NexImmune | Downgrades: Neutral | n/a | $3.46 | - | 2 | Nov 16, 2022 | |
| BIIB Biogen | Maintains: Neutral | n/a | $222.75 | - | 4 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $9.61 | +212.17% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | n/a | $4.66 | - | 1 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | n/a | $418.99 | - | 3 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | n/a | $1.33 | - | 1 | Mar 8, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | n/a | $3.90 | - | 1 | Feb 25, 2021 | |
| AMGN Amgen | Maintains: Overweight | n/a | $312.86 | - | 6 | Feb 3, 2021 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | n/a | $23.58 | - | 1 | Oct 12, 2020 | |
| GILD Gilead Sciences | Maintains: Overweight | n/a | $64.58 | - | 2 | Aug 19, 2020 | |
| TGTX TG Therapeutics | Maintains: Overweight | n/a | $16.92 | - | 1 | May 6, 2020 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | n/a | $1.39 | - | 1 | May 5, 2020 | |
| ASND Ascendis Pharma | Reiterates: Overweight | n/a | $133.13 | - | 5 | Apr 20, 2020 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | n/a | $31.05 | - | 3 | Apr 8, 2020 | |
| PACB Pacific Biosciences of California | Assumes: Overweight | n/a | $1.72 | - | 1 | Mar 9, 2020 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Overweight | n/a | $5.17 | - | 1 | Mar 6, 2020 | |
| SRPT Sarepta Therapeutics | Reiterates: Overweight | n/a | $132.30 | - | 7 | Feb 27, 2020 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $32.92 | - | 4 | Feb 14, 2020 | |
| INCY Incyte | Maintains: Neutral | n/a | $53.50 | - | 2 | Jan 3, 2020 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $26.23 | - | 2 | Jul 19, 2018 | |
| MESO Mesoblast | Downgrades: Underperform | n/a | $7.17 | - | 3 | Mar 22, 2018 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | n/a | $151.37 | - | 3 | Mar 13, 2018 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $81.72 | - | 2 | Mar 2, 2018 | |
| PBYI Puma Biotechnology | Maintains: Outperform | n/a | $4.79 | - | 4 | Jan 24, 2018 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | n/a | $24.86 | - | 1 | Nov 3, 2017 | |
| DRI Darden Restaurants | Maintains: Neutral | n/a | $146.92 | - | 1 | Sep 27, 2017 | |
| UTHR United Therapeutics | Initiates: Underperform | n/a | $266.05 | - | 1 | Mar 16, 2017 | |
| ACIU AC Immune | Initiates: Outperform | n/a | $2.35 | - | 1 | Oct 18, 2016 |
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $968.00
Upside: -12.19%
Arcus Biosciences
Sep 12, 2023
Reiterates: Overweight
Price Target: $46
Current: $16.15
Upside: +184.83%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $16.95
Upside: +6.19%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $16.51
Upside: +263.42%
Longboard Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $21.99
Upside: -27.24%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.40
Upside: +275.00%
Arrowhead Pharmaceuticals
Aug 8, 2023
Maintains: Overweight
Price Target: $79 → $47
Current: $24.72
Upside: +90.13%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $11.92
Upside: +185.23%
NexImmune
Nov 16, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.46
Upside: -
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: n/a
Current: $222.75
Upside: -
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $9.61
Upside: +212.17%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: n/a
Current: $4.66
Upside: -
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: n/a
Current: $418.99
Upside: -
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.33
Upside: -
Fate Therapeutics
Feb 25, 2021
Maintains: Overweight
Price Target: n/a
Current: $3.90
Upside: -
Amgen
Feb 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $312.86
Upside: -
Bicycle Therapeutics
Oct 12, 2020
Initiates: Overweight
Price Target: n/a
Current: $23.58
Upside: -
Gilead Sciences
Aug 19, 2020
Maintains: Overweight
Price Target: n/a
Current: $64.58
Upside: -
TG Therapeutics
May 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $16.92
Upside: -
Marinus Pharmaceuticals
May 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $1.39
Upside: -
Ascendis Pharma
Apr 20, 2020
Reiterates: Overweight
Price Target: n/a
Current: $133.13
Upside: -
PTC Therapeutics
Apr 8, 2020
Reiterates: Overweight
Price Target: n/a
Current: $31.05
Upside: -
Pacific Biosciences of California
Mar 9, 2020
Assumes: Overweight
Price Target: n/a
Current: $1.72
Upside: -
Aurinia Pharmaceuticals
Mar 6, 2020
Maintains: Overweight
Price Target: n/a
Current: $5.17
Upside: -
Sarepta Therapeutics
Feb 27, 2020
Reiterates: Overweight
Price Target: n/a
Current: $132.30
Upside: -
Agios Pharmaceuticals
Feb 14, 2020
Reiterates: Overweight
Price Target: n/a
Current: $32.92
Upside: -
Incyte
Jan 3, 2020
Maintains: Neutral
Price Target: n/a
Current: $53.50
Upside: -
AnaptysBio
Jul 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $26.23
Upside: -
Mesoblast
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $7.17
Upside: -
Alnylam Pharmaceuticals
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $151.37
Upside: -
BioMarin Pharmaceutical
Mar 2, 2018
Maintains: Outperform
Price Target: n/a
Current: $81.72
Upside: -
Puma Biotechnology
Jan 24, 2018
Maintains: Outperform
Price Target: n/a
Current: $4.79
Upside: -
Intellia Therapeutics
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $24.86
Upside: -
Darden Restaurants
Sep 27, 2017
Maintains: Neutral
Price Target: n/a
Current: $146.92
Upside: -
United Therapeutics
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $266.05
Upside: -
AC Immune
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.35
Upside: -